PL373903A1 - Połączenie antagonisty NMDA i inhibitorów acetylocholinoesterazy do leczenia choroby Alzheimera - Google Patents

Połączenie antagonisty NMDA i inhibitorów acetylocholinoesterazy do leczenia choroby Alzheimera

Info

Publication number
PL373903A1
PL373903A1 PL03373903A PL37390303A PL373903A1 PL 373903 A1 PL373903 A1 PL 373903A1 PL 03373903 A PL03373903 A PL 03373903A PL 37390303 A PL37390303 A PL 37390303A PL 373903 A1 PL373903 A1 PL 373903A1
Authority
PL
Poland
Prior art keywords
nmda
antagonist
alzheimer
disease
treatment
Prior art date
Application number
PL03373903A
Other languages
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
H.Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373903(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H.Lundbeck A/S filed Critical H.Lundbeck A/S
Publication of PL373903A1 publication Critical patent/PL373903A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03373903A 2002-05-31 2003-05-22 Połączenie antagonisty NMDA i inhibitorów acetylocholinoesterazy do leczenia choroby Alzheimera PL373903A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31

Publications (1)

Publication Number Publication Date
PL373903A1 true PL373903A1 (pl) 2005-09-19

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03373903A PL373903A1 (pl) 2002-05-31 2003-05-22 Połączenie antagonisty NMDA i inhibitorów acetylocholinoesterazy do leczenia choroby Alzheimera

Country Status (17)

Country Link
EP (1) EP1509232B1 (pl)
JP (1) JP2005528431A (pl)
AT (1) ATE414519T1 (pl)
AU (1) AU2003227516B2 (pl)
BR (1) BR0311375A (pl)
CY (1) CY1108725T1 (pl)
DE (1) DE60324788D1 (pl)
DK (1) DK1509232T3 (pl)
ES (1) ES2314200T3 (pl)
IL (1) IL165255A0 (pl)
MX (1) MXPA04011762A (pl)
NO (1) NO332754B1 (pl)
NZ (1) NZ536603A (pl)
PL (1) PL373903A1 (pl)
PT (1) PT1509232E (pl)
SI (1) SI1509232T1 (pl)
WO (1) WO2003101458A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274353B2 (en) * 2002-10-24 2007-04-05 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
DK1703902T3 (da) * 2004-01-05 2011-02-14 Merz Pharma Gmbh & Co Kgaa Memantin til behandling af mild til moderat Alzheimer's sygdom
JP2007518755A (ja) * 2004-01-22 2007-07-12 ノイロサーチ アクティーゼルスカブ モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
WO2005092009A2 (en) * 2004-03-19 2005-10-06 Axonyx, Inc. Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1827385B1 (en) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
NZ562120A (en) * 2005-04-28 2010-07-30 Eisai R&D Man Co Ltd Composition comprising donepezil and memantine as antidementia agents
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
PL2590696T3 (pl) 2010-07-05 2017-08-31 Gambro Lundia Ab Ambulatoryjne urządzenie do ultrafiltracji, powiązane sposoby i produkt w postaci programu komputerowego
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
SI3458039T1 (sl) * 2016-05-18 2020-11-30 Suven Life Sciences Limited, Trojna kombinacija čistih 5-HT6 receptor antagonistov, inhibitorjev acetilholinesteraze in NMDA receptor antagonistov
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
US20190269627A1 (en) * 2016-10-28 2019-09-05 Chase Pharmaceuticals Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020240505A1 (en) 2019-05-31 2020-12-03 TECNIMEDE - Sociedade Técnico-medicinal, SA Immediate release fixed-dose combination of memantine and donepezil

Also Published As

Publication number Publication date
DE60324788D1 (de) 2009-01-02
ES2314200T3 (es) 2009-03-16
AU2003227516B2 (en) 2008-03-20
PT1509232E (pt) 2009-01-07
JP2005528431A (ja) 2005-09-22
IL165255A0 (en) 2005-12-18
DK1509232T3 (da) 2009-02-23
MXPA04011762A (es) 2005-03-31
AU2003227516A1 (en) 2003-12-19
SI1509232T1 (sl) 2009-04-30
CY1108725T1 (el) 2014-04-09
EP1509232B1 (en) 2008-11-19
BR0311375A (pt) 2005-03-15
ATE414519T1 (de) 2008-12-15
NO20045434L (no) 2004-12-13
NZ536603A (en) 2007-06-29
EP1509232A1 (en) 2005-03-02
WO2003101458A1 (en) 2003-12-11
NO332754B1 (no) 2013-01-07

Similar Documents

Publication Publication Date Title
PL373903A1 (pl) Połączenie antagonisty NMDA i inhibitorów acetylocholinoesterazy do leczenia choroby Alzheimera
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU7031500A (en) Therapeutic quinazoline compounds
BG107515A (en) Therapeutic combination
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
GB0005251D0 (en) Therapeutic compounds
WO1999005096A3 (en) Urokinase inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE234282T1 (de) Polymorphe verbindungen
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
MXPA05012955A (es) Composiciones farmaceuticas de atorvastatina.
GB9907571D0 (en) Compounds
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
SE0004827D0 (sv) Therapeutic compounds
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity
WO2006020853A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)